Clinicopathologic implications of tissue inhibitor of metalloproteinase-1- positive diffuse large B-cell lymphoma

Modern Pathology

Volumn 19, Issue 7, 2006, Pages 963-973

  Choi, Jung Woo ^a   An, Jung Suk ^a   Lee, Ju Han ^a   Lee, Eung Seok ^a   Kim, Kwang Hee ^b   Kim, Young Sik ^a  

^a Korea University College of Medicine   (South Korea)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Non Hodgkin lymphoma; TIMP 1; Tissue microarray

Indexed keywords

LACTATE DEHYDROGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; AGING; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER SURVIVAL; CLINICAL FEATURE; CLUSTER ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENDOTHELIUM CELL; EPSTEIN BARR VIRUS; FEMALE; FIBROBLAST; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CONTENT; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RISK ASSESSMENT; SCORING SYSTEM; STROMA CELL; SYMPTOM; TISSUE MICROARRAY; TUMOR CELL; UNIVARIATE ANALYSIS; VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CLUSTER ANALYSIS; DNA-BINDING PROTEINS; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HUMANS; INTERFERON REGULATORY FACTORS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; NEPRILYSIN; PROGNOSIS; RETROSPECTIVE STUDIES; STROMAL CELLS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 33745207537     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800615     Document Type: Article

References (62)

1. Hayakawa T, Yamashita K, Tanzawa K, et al. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 1992;298:29-32.
2. Khokha R. Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. J Natl Cancer Inst 1994;86:299-304.
3. Guedez L, Martinez A, Zhao S, et al. Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/ plasmablastic tumors. Blood 2005;105:1660-1668.
4. Kossakowska AE, Urbanski SJ, Edwards DR. Tissue inhibitor of metalloproteinases-1 (TIMP-1) RNA is expressed at elevated levels in malignant non-Hodgkin's lymphomas. Blood 1991;77:2475-2481.
5. Kossakowska AE, Urbanski SJ, Watson A, et al. Patterns of expression of metalloproteinases and their inhibitors in human malignant lymphomas. Oncol Res 1993;5:19-28.
6. Yoshikawa T, Saitoh M, Tsuburaya A, et al. Tissue inhibitor of matrix metalloproteinase-1 in the plasma of patients with gastric carcinoma. A possible marker for serosal invasion and metastasis. Cancer 1999;86:1929-1935.
7. Holten-Andersen MN, Stephens RW, Nielsen HJ, et al. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res 2000;6:4292-4299.
8. Guedez L, Courtemanch L, Stetler-Stevenson M. Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells. Blood 1998;92:1342-1349.
9. The non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997;89:3909-3918.
10. Coiffier B. Diffuse large cell lymphoma. Curr Opin Oncol 2001;13:325-334.
11. Rossi D, Gaidano G. Molecular heterogeneity of diffuse large B-cell lymphoma: implications for disease management and prognosis. Hematology 2002;7:239-252.
12. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511.
13. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-1947.
14. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003;198:851-862.
15. Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005;105:1851-1861.
16. Kuze T, Nakamura N, Hashimoto Y, et al. The characteristics of Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma: comparison between EBV(+) and EBV(-) cases in Japanese population. Jpn J Cancer Res 2000;91:1233-1240.
17. Hummel M, Anagnostopoulos I, Korbjuhn P, et al. Epstein-Barr virus in B-cell non-Hodgkin's lymphomas: unexpected infection patterns and different infection incidence in low- and high-grade types. J Pathol 1995;175:263-271.
18. Jaffe ES HN, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001.
19. Hans CP, Weisenburger DD, Greiner TC, et al. Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Pathol 2005;18:1377-1384.
20. Natkunam Y, Warnke RA, Montgomery K, et al. Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry. Mod Pathol 2001;14:686-694.
21. Hedvat CV, Hegde A, Chaganti RS, et al. Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hum Pathol 2002;33:968-974.
22. Milanes-Yearsley M, Hammond ME, Pajak TF, et al. Tissue micro-array: a cost and time-effective method for correlative studies by regional and national cancer study groups. Mod Pathol 2002;15:1366-1373.
23. Lai R, Rassidakis GZ, Medeiros LJ, et al. Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Am J Pathol 2004;164:2251-2258.
24. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282.
25. Liu CL, Prapong W, Natkunam Y, et al. Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. Am J Pathol 2002;161:1557-1565.
26. Eisen MB, Spellman PT, Brown PO, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998;95:14863-14868.
27. Ko YH, Kim CW, Park CS, et al. REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer 1998;83:806-812.
28. Leung YF, Cavalieri D. Fundamentals of cDNA microarray data analysis. Trends Genet 2003;19:649-659.
29. Maesako Y, Uchiyama T, Ohno H. Comparison of gene expression profiles of lymphoma cell lines from transformed follicular lymphoma, Burkitt's lymphoma and de novo diffuse large B-cell lymphoma. Cancer Sci 2003;94:774-781.
30. Rust R, Blokzijl T, Harms G, et al. TIMP-1 expression in anaplastic large cell lymphoma is usually restricted to macrophages and only seldom observed in tumour cells. J Pathol 2005;206:445-450.
31. Oelmann E, Herbst H, Zuhlsdorf M, et al. Tissue inhibitor of metalloproteinases 1 is an autocrine and paracrine survival factor, with additional immune-regulatory functions, expressed by Hodgkin/Reed-Sternberg cells. Blood 2002;99:258-267.
32. Pennanen H, Kuittinen O, Soini Y, et al. Clinicopathological correlations of TIMP-1 and TIMP-2 in Hodgkin's lymphoma. Eur J Haematol 2004;72:1-9.
33. Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 2005;106:1164-1174.
34. Zhao WQ, Li H, Yamashita K, et al. Cell cycle-associated accumulation of tissue inhibitor of metalloproteinases-1 (TIMP-1) in the nuclei of human gingival fibroblasts. J Cell Sci 1998;111(Part 9):1147-1153.
35. Ritter LM, Garfield SH, Thorgeirsson UP. Tissue inhibitor of metalloproteinases-1 (TIMP-1) binds to the cell surface and translocates to the nucleus of human MCF-7 breast carcinoma cells. Biochem Biophys Res Commun 1999;257:494-499.
36. Lu J, Chua HH, Chen SY, et al. Regulation of matrix metalloproteinase-1 by Epstein-Barr virus proteins. Cancer Res 2003;63:256-262.
37. Takeshita H, Yoshizaki T, Miller WE, et al. Matrix metalloproteinase 9 expression is induced by Epstein-Barr virus latent membrane protein 1 C-terminal activation regions 1 and 2. J Virol 1999;73:5548-5555.
38. Horikawa T, Yoshizaki T, Sheen TS, et al. Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma. Cancer 2000;89:715-723.
39. Liu LT, Peng JP, Chang HC, et al. RECK is a target of Epstein-Barr virus latent membrane protein 1. Oncogene 2003;22:8263-8270.
40. Noda M, Oh J, Takahashi R, et al. RECK: a novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling. Cancer Metast Rev 2003;22:167-175.
41. Lambert E, Dasse E, Haye B, et al. TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004;49:187-198.
42. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000;1477:267-283.
43. Ree AH, Florenes VA, Berg JP, et al. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res 1997;3:1623-1628.
44. McCarthy K, Maguire T, McGreal G, et al. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer 1999;84:44-48.
45. Nakopoulou L, Giannopoulou I, Stefanaki K, et al. Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J Pathol 2002;197:307-313.
46. Schrohl AS, Christensen IJ, Pedersen AN, et al. Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer. Mol Cell Proteomics 2003;2:164-172.
47. Schrohl AS, Holten-Andersen MN, Peters HA, et al. Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res 2004;10:2289-2298.
48. Li G, Fridman R, Kim HR. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res 1999;59:6267-6275.
49. Liu XW, Bernardo MM, Fridman R, et al. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway. J Biol Chem 2003;278:40364-40372.
50. Liu XW, Taube ME, Jung KK, et al. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Res 2005;65:898-906.
51. Lee SJ, Yoo HJ, Bae YS, et al. TIMP-1 inhibits apoptosis in breast carcinoma cells via a pathway involving pertussis toxin-sensitive G protein and c-Src. Biochem Biophys Res Commun 2003;312:1196-1201.
52. Guedez L, Stetler-Stevenson WG, Wolff L, et al. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest 1998;102:2002-2010.
53. Hsieh FC, Cheng G, Lin J. Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem Biophys Res Commun 2005;335:292-299.
54. van der Voort R, Keehnen RM, Beuling EA, et al. Regulation of cytokine signaling by B cell antigen receptor and CD40-controlled expression of heparan sulfate proteoglycans. J Exp Med 2000;192:1115-1124.
55. Bates RC, Edwards NS, Burns GF, et al. A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells. Cancer Res 2001;61:5275-5283.
56. Lin YH, Yang-Yen HF. The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem 2001;276:46024-46030.
57. Lakshman M, Subramaniam V, Rubenthiran U, et al. CD44 promotes resistance to apoptosis in human colon cancer cells. Exp Mol Pathol 2004;77:18-25.
58. Tzankov A, Pehrs AC, Zimpfer A, et al. Prognostic significance of CD44 expression in diffuse large B cell lymphoma of activated and germinal centre B cell-like types: a tissue microarray analysis of 90 cases. J Clin Pathol 2003;56:747-752.
59. Biasoli I, Morais JC, Scheliga A, et al. CD10 and Bcl-2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large-cell lymphoma with very good or very poor prognoses. Histopathology 2005;46:328-333.
60. Chang CC, McClintock S, Cleveland RP, et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 2004;28:464-470.
61. Jerkeman M, Anderson H, Dictor M, et al. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma - a Nordic Lymphoma Group study. Ann Hematol 2004;83:414-419.
62. Moller MB, Pedersen NT, Christensen BE. Factors predicting long-term survival in low-risk diffuse large B-cell lymphoma. Am J Hematol 2003;74:94-98.